PCRX VS NVCR Stock Comparison
Performance
PCRX10/100
10/100
PCRX returned -42.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
NVCR10/100
10/100
NVCR returned -84.90% in the last 12 months. Based on SPY's performance of -14.03%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
PCRX67/100
67/100
16 analysts offer 12-month price targets for PCRX. Together, they have an average target of 57.5, the most optimistic target put PCRX at 63 within 12-months and the most pessimistic has PCRX at 52.
NVCR79/100
79/100
6 analysts offer 12-month price targets for NVCR. Together, they have an average target of 136.5, the most optimistic target put NVCR at 200 within 12-months and the most pessimistic has NVCR at 99.
Technicals
PCRX21/100
21/100
PCRX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.
NVCR36/100
36/100
NVCR receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.
Earnings
PCRX10/100
10/100
PCRX has missed earnings 8 times in the last 20 quarters.
NVCR10/100
10/100
NVCR has missed earnings 11 times in the last 20 quarters.
Profit
PCRX55/100
55/100
Out of the last 20 quarters, PCRX has had 12 profitable quarters and has increased their profits year over year on 8 of them.
NVCR30/100
30/100
Out of the last 20 quarters, NVCR has had 6 profitable quarters and has increased their profits year over year on 4 of them.
Volatility
PCRX45/100
45/100
PCRX has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
NVCR31/100
31/100
NVCR has had a lower than average amount of volatility over the last 12 months giving it a score of 30 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Pacira BioSciences, Inc. Common Stock Summary
Nasdaq / PCRX
Healthcare
Drug Manufacturers - Specialty & Generic
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
NovoCure Limited Ordinary Shares Summary
Nasdaq / NVCR
Healthcare
Medical - Instruments & Supplies
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare PCRX to other companies in the same or a similar industry.
